IL6 and neoplasm: IL-6 derived from PMN endows metastatic tumour cells with proliferative advantages [67, 68, 281] and the resistance to cytotoxic T cells through the overexpression of immunosuppressive molecules like PD-L1 [282], which suggests that IL-6 is a promising target for both restriction of tumour proliferation and restoration of host immunity.